

University of Groningen

Host cell responses to dengue virus infection

Diosa Toro, Mayra

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2017

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Diosa Toro, M. (2017). *Host cell responses to dengue virus infection*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

2

ARTHROPOD-BORNE FLAVIVIRUSES AND RNA INTERFERENCE: SEEKING NEW APPROACHES FOR ANTIVIRAL THERAPY

Mayra Diosa-Toro, Silvio Urcuqui-Inchima, Jolanda M. Smit

Advances in Virus Research, 2013; 85: 91-111

Abstract

Flaviviruses are the most prevalent arthropod-borne viruses worldwide, and nearly half of the 70 Flavivirus members identified are human pathogens. Despite the huge clinical impact of flaviviruses, there is no specific human antiviral therapy available to treat infection with any of the flaviviruses. Therefore, there is a continued search for novel therapies, and this review describes the current knowledge on the usage of RNA interference (RNAi) in combating flavivirus infections. RNAi is a process of sequence-specific gene silencing triggered by double-stranded RNA. Antiviral RNAi strategies against arthropod-borne flaviviruses have been reported and although several hurdles must be overcome to employ this technology in clinical applications, they potentially represent a new therapeutic tool.

1. Introduction

The genus *Flavivirus* of the family *Flaviviridae* comprises more than 70 enveloped RNA viruses and depending on the virus can cause disease and mortality in humans and animals. Flaviviruses are arthropod-borne viruses (arboviruses) and most of them are transmitted to vertebrates by mosquitoes or ticks¹. Important human pathogens are Dengue virus (DENV), West Nile virus (WNV), Yellow fever virus (YFV), and Japanese encephalitis virus (JEV)². These viruses cause major outbreaks with a variety of disease symptoms, including encephalitis and hemorrhagic fever. In severe cases, the mortality rates range from below 1% to 50%^{3–6}.

Currently, effective vaccines are in use for YFV⁷, JEV⁸, and tick-borne encephalitis virus (TBEV)⁹ but not for other flaviviruses. Furthermore, there is no specific antiviral therapy available for any of them. For the rational design of vaccines and therapeutic drugs, it is imperative to understand the molecular interplay between the host and the pathogen. In recent years, extensive progress has been made in this area and one of the important discoveries is the role of RNAi in controlling flavivirus infections.

RNAi is a conserved process of gene silencing, and due to its ability to control viral and host gene expression, it is considered a key determinant in the replication machinery of viruses and consequently in the pathogenesis of disease¹⁰. The two primary effector molecules of the RNAi pathway are microRNAs (miRNAs) and small interfering RNAs (siRNAs)^{11,12}. RNAi can act to reduce viral loads by inhibition of viral protein expression and transcription of viral genomes¹⁰. The RNAi strategy has been shown to be effective against multiple mammalian host viruses such as Coronavirus¹³, vesicular stomatitis virus¹⁴, human immunodeficiency virus (HIV)¹⁵, H1N1 influenza A virus¹⁶ and hepatitis C virus (HCV)¹⁷.

In this review, we will discuss a compilation of papers in which RNAi has been suggested as a potential therapy against the most commonly distributed flaviviruses. We will begin with the description of the RNAi mechanism and its antiviral features, as well as some general characteristics of the genus *Flavivirus*. Then, we will summarize the studies that have been reported in the field of RNAi against flaviviruses and its vectors. Finally, the challenges that need to be overcome in order to improve siRNA delivery and its applicability to prevent or treat infections by flaviviruses will be discussed.

2. The RNA interference mechanism and its antiviral effects

The effector molecules of the RNAi mechanism are small RNA molecules of 20–30 nucleotides in length. There are several categories of small RNAs, and in this review, I will focus on the two most described molecules, miRNAs and siRNAs. The processing and generation of miRNAs and siRNAs is depicted in Fig.1. Within the nucleus, pri-miRNA molecules are generated by RNA polymerase II transcription¹⁸. These pri-miRNA molecules have a hairpin-shaped structure and are about 70 nucleotides in length. The double-stranded RNA structure within the hairpin is subsequently recognized by a nuclear protein called DiGeorge syndrome critical region 8 (DGCR8)¹⁹. Thereafter, DGCR8 interacts with the RNA-cutting enzyme Drosha to generate miRNA precursors (pre-miRNAs). The pre-miRNAs are then transported to the cytoplasm by Exportin-5^{20,21}. Once in the cytoplasm, the pre-miRNAs are cleaved into 22-nt mature miRNAs by an RNase III-like enzyme termed Dicer²². The mature miRNA duplex then undergoes an ATP-dependent unwinding process and a single strand is loaded onto the RNA-induced silencing complex (RISC). The miRNA binds to miRNA recognition elements (MRE) which are mostly located in the 3' untranslated region (3'UTR) of mRNAs²³. Binding of a miRNA to its mRNA target typically leads to translational repression and exonucleolytic mRNA decay, although highly complementary targets can be cleaved endo-nucleolytically as well²⁴.

Several methodologies have been developed to exploit the RNAi mechanism. For example, miRNA functioning can be mimicked through the introduction of a plasmid or viral vector encoding short hairpin RNA (shRNA) molecules into the cell²⁵. Furthermore, it has been shown that exogenous dsRNA molecules can also be incorporated in the RNAi pathway. The dsRNA molecules can be transfected into the cell cytoplasm, taken up from the environment, or produced in virus-infected cells as RNA replicative intermediates²⁶. These dsRNA molecules are then processed by Dicer into siRNAs. Alternatively, exogenous synthetic 21–29 nt siRNAs can be transfected directly into the cytoplasm²⁷. The siRNA molecules undergo an ATP-dependence unwinding process and a single strand is incorporated in the RISC complex, similarly as with the processing of miRNAs. In contrast to miRNAs, siRNAs only induce degradation of the perfectly base-paired target mRNA²⁸.




FIGURE 1 | RNA interference (RNAi). RNAi is a post-transcriptional gene silencing mechanism that regulates gene expression and mediates resistance against pathogenic nucleic acids. The main effector molecules of RNAi are miRNAs and siRNAs. MiRNAs are encoded in the genome and transcribed into primary miRNA transcripts (pri-miRNAs). Pri-miRNAs are processed to miRNA precursors (pre-miRNAs) in the nucleus by the RNase III-like enzyme Drosha and the DiGeorge syndrome critical region 8 (DGCR8). Pre-miRNAs are transported to the cytoplasm by exportin 5, where they are cleaved by Dicer to yield ~19–23 nt miRNA duplexes. One strand is then selected and loaded in the RNA-induced silencing complex (RISC). The key components of RISC are proteins of the Argonaute (AGO) family which mediate translational repression or cleavage of target mRNAs. Furthermore, dsRNA molecules are targets for the RNAi pathway. These dsRNA molecules are artificially introduced in the cell cytoplasm or are virus RNAs. Like miRNA precursors, long dsRNA are processed by Dicer into ~21 nt siRNA duplexes. One strand of the siRNA is selected and loaded into RISC. The binding of an siRNA to its target mRNA typically induces degradation.

Besides regulation of gene expression, RNAi in plants, insects, nematodes, and fungi play an essential role in the antiviral response via virus-specific siRNAs^{29–31}. In virus-infected mammalian cells, small RNAs have been identified^{32,33} but it remains unclear whether they contribute to an antiviral response^{10,34}. In contrast, mammalian-encoded miRNAs have been reported to target and inhibit viral gene expression. For example, miRNA miR-32 targets two different sequences (located in the 3'UTR and the open reading frame 2) in the genome of primate foamy virus type 1, thereby inhibiting viral translation and replication³⁵. Furthermore, similar findings were reported for miR-24 and miR-93 in vesicular stomatitis virus infection¹⁴; miR-29a during HIV infection¹⁵; and miR-323, -491, and -654 in influenza H1N1 infection¹⁶. These findings are indicative for the importance of the host RNAi in modulating the replication efficiency of the infecting viruses and point out that harnessing this pathway could represent a powerful antiviral method.

3. Arthropod-borne flaviviruses

Flaviviruses are spherical particles with a diameter of approximately 50 nm. The viral genome consists of a single-stranded positive-sense RNA molecule which is approximately 11 kb in length. The RNA molecule contains highly structured 5' and 3'UTRs and has one open reading frame^{36,37}. The RNA is packaged by multiple copies of the capsid (C) protein (nucleocapsid) and is surrounded by a host-derived lipid membrane in which two structural transmembrane proteins are inserted, the envelope glycoprotein E and the membrane protein M.

Infection with one of the arthropod-borne flaviviruses begins when the vector takes a blood meal thereby injecting the virus into the dermis of the host. The reproductive cycle of flaviviruses starts with attachment of the virus to cell-surface receptors. Upon virus–receptor interaction, the particle is internalized by receptor-mediated endocytosis and delivered to endosomes³⁸. Within the acidic lumen of the endosome, fusion of the viral and cellular membranes is triggered by the viral E glycoprotein allowing the release of the nucleocapsid into the cell cytoplasm³⁹. Following nucleocapsid uncoating, the RNA is translated into a polyprotein of about 3400 amino acids in length. The polyprotein is subsequently processed by viral and host cellular proteases yielding the three structural proteins (C, prM, and E) and seven nonstructural proteins (NS1, 2A, 2B, 3, 4A, 4B, and NS5)^{36,40}. The prM and E proteins are translocated across the endoplasmic reticulum (ER) membrane and form heterodimers that are oriented into the lumen of the ER. The NS proteins assemble and form a viral RNA replication complex^{40,41}. RNA synthesis is regulated by the 5'–3'CS and 5'–3'UAR inverted complementary sequences that allow the circularization

of the genome⁴². After genome cyclization, the RNA-dependent RNA polymerase, NS5, synthesizes the complementary minus-strand RNA molecule from the genomic RNA, which subsequently acts as a template for the synthesis of new positive-sense viral RNA^{43,44}. The newly synthesized positive-sense RNA molecule interacts with multiple copies of the C protein to form a nucleocapsid⁴⁵. The nucleocapsid then buds into the ER thereby acquiring a lipid bilayer containing heterodimers of the prM and E proteins. The prM protein acts as a scaffold to prevent premature fusion of the virus during its transport out of the cell⁴⁶. During the secretory pathway, virion maturation occurs in the trans-Golgi network through furin-mediated cleavage of the prM protein to M and a pr peptide⁴⁷. The pr peptide dissociates after the release of the virion into the extracellular milieu and allows new progeny virus particles to bind and infect a new permissive host cell via receptor-mediated endocytosis. In Fig. 2 the life cycle of flaviviruses is depicted.




FIGURE 2 | Flavivirus life cycle. Flaviviruses bind to cellular receptors on the surface of susceptible host cells (1). Virions are internalized by endocytosis (2). The acidic environment within the endosomes induces fusion (3) between the viral and cell membranes resulting in the release of the RNA genome (4). The RNA genome of flaviviruses contains a single open reading frame and highly structured 3' and 5'UTRs. The RNA is translated into a polyprotein precursor that is processed into three structural proteins and seven non-structural proteins (5). The complementary sequences CS (cyclization sequence) and UAR (upstream AUG regions) at both ends of the genome allow its circularization, a required step for replication. Replication is mediated by the nonstructural proteins. Virus assembly occurs in the endoplasmic reticulum (ER) (6). The resultant immature particles are transported through the Golgi network where furin-mediated cleavage of prM to M generates mature infectious particles (7) that are released by exocytosis (8).

3.1. West Nile virus

The natural hosts of WNV are birds, but humans, horses, and other mammals can also be infected⁴⁸. The virus is transmitted by a vast range of mosquitoes and depending on the geographical region, different species are responsible for the transmission of the virus. The most important vectors are bird-feeding mosquitoes of the *Culex* genus⁴⁸. Approximately 20% of the infected people develop a classical West Nile fever (flu-like symptoms with high fever), and in about 1% of the cases, severe neurological complications, such as encephalitis, meningitis, or flaccid paralysis are seen. In the latest group, the mortality rate can reach 20%⁵.

The prophylactic potential of exogenous siRNAs against WNV infection was highlighted several years ago. McCown *et al.* constructed DNA vectors encoding siRNAs targeting the C and NS5 genes of WNV and transfected these into 293T cells 24 h prior to WNV infection. The number of E-positive cells was 30% and 83% lower in cells transfected with the plasmid encoding the siRNA against C and NS5, respectively. In addition, a decrease in RNA levels (65%) and virus particle production (60%) was achieved in cells transfected with the siRNA against C⁴⁹. Similar results were observed in Vero cells using siRNAs targeting the NS5 gene⁵⁰ and the E gene⁵¹ and in HTB-11 cells when the C gene was targeted⁵². Also, WNV replication and virus particle production was found attenuated when siRNAs were applied targeting the 3'UTRs of the viral genome⁵³. Taken together, these observations indicate that pretreatment of cells with siRNAs directed against the WNV genome results in a significant inhibition of WNV replication.

The therapeutic effect of siRNAs to WNV infection is limited and appears to be dependent on the transfection methodology applied. Geiss *et al.*⁵⁴, observed that siRNAs targeting the C gene had no effect on virus replication when transfected into cells 10 h after WNV infection using lipid-based reagents. In addition, no significant reduction in viral protein or RNA levels was seen in WNV replicon-expressing cells transfected with siRNAs targeting the NS3 gene using lipid-based reagents. On the other hand, however, a 10-fold reduction in NS3 protein expression and a 7.5-fold decrease in RNA levels were observed when the siRNA molecules were delivered to the cell cytoplasm by electroporation. These results indicate that transient opening of membrane structures is required to induce RNAi during active WNV replication. However, a word of caution is in place here as siRNA transfection with oligofectamine, also a lipid-based reagent, was found to reduce HCV protein expression and RNA replication in HCV replicon-expressing cells⁵⁵.

The different efficacy of siRNA treatment before and after WNV infection is supported by in vivo data in mice. Bai *et al.* reported that mice are protected from fatal infection with WNV when siRNAs targeting the E gene are administered 24 h before the virus

challenge, but failed to protect when the siRNA is given 24 h after virus challenge⁵¹. Furthermore, Ye et al. observed that the administration of siRNAs toward NS5 and C genes failed to protect mice when given 2 days postinfection with WNV⁵⁶.

3.2. Dengue virus

Dengue is the most prevalent vector-borne disease in the world with an estimated 50 million cases each year in (sub)tropical regions³. The virus is predominantly transmitted to humans through the mosquito *Aedes aegypti*, but *Aedes albopictus* can act as a vector as well. Four antigenically distinct viruses designated from 1 to 4 (DENV 1–4) have been identified so far. Infection with any of the four DENV serotypes can give a broad spectrum of clinical manifestations ranging from acute self-limiting febrile illness to life-threatening complications like hemorrhagic fever and dengue shock. Individuals that develop severe disease often have preexisting anti-dengue immunity generated during previous heterologous DENV infections or received anti-dengue antibodies from their mother⁵⁷. The immunopathogenesis of severe disease is complex and see references for reviews on this topic^{57,58}. In the past few decades, dengue disease has become a major health problem due to increased endemic activity and emergence to previously non-endemic regions².

The first evidence of an RNAi-mediated antiviral mechanism during DENV infection was obtained by Olson and colleagues. The authors showed that transient or stable expression of long dsRNAs cognate to the DENV-2 genome in *A. albopictus* (C6/36) cells inhibited subsequent infection of these cells with DENV-2^{59–62}. Similar results were observed in dsRNA transduced female *A. aegypti* mosquitoes^{59–62}. Furthermore, Wu et al. found that a synthetic siRNA molecule targeting a sequence in the prM protein-coding region reduced the cytopathic effect in C6/36 cells and increased cell survival more than twofold⁶³.

The therapeutic potential of siRNA for DENV infection in mammalian cells has also been described. For example, adeno-associated virus vectors carrying siRNA against the CS1 region (a conserved sequence in the 3'UTR of all four DENV serotypes) decreased the percentage of DENV-infected human monocyte-derived dendritic cells (MDDC) and reduced apoptosis of the infected cells. The observed attenuated but prolonged virus particle production may be beneficial as activation of humoral and cellular immune responses is considered to help with the clearance of DENV particles⁶⁴. In addition, Subramanya et al. reported 80% reduction in infection of MDDC when cells were treated with siRNAs targeting E gene after DENV infection⁶⁵. In this study, the authors used a novel peptide-based delivery system that allows targeting of siRNAs to human DCs both in vitro as well as in in vivo models⁶⁵.

Importantly, the effectiveness of RNAi against DENV infection has also been verified in vivo⁶⁶. Retro-orbital intravenous injection of three doses of siRNA molecules (targeting a conserved sequence in the 5'CS region) in mice at 24 h pre- and 24 and 72 h-postchallenge with DENV revealed that siRNA treatment increases the average survival, and significantly reduces viral loads in several tissues and at different time-points postinfection⁶⁶.

In addition to the use of exogenous siRNAs to restrict DENV replication, the antiviral function of endogenous miRNAs has also been described. In these studies, engineered viruses were used that contain MREs for cellular miRNAs within the viral genome^{67,68}. It was found that the insertion of the MRE for the hepatic-specific miR-122 in the 3'UTR of DENV genome suppresses the viral replication in transfected cells⁶⁸. Moreover, using a chimeric DENV/TBEV virus (C, prM, E from TBEV), it was shown that the inclusion of the MRE for the brain-expressed miR-9 and miR-124a, reduces the access of the virus to the central nervous system and consequently the development of lethal encephalitis in mice⁶⁷.

Another approach that has been explored is to reduce DENV replication by modulating host gene expression. For instance, downregulation of the heat shock protein 60 by RNAi in DENV-infected U937 cells decreased viral replication and particle production significantly⁶⁹. In another study, the cell-surface receptor GRP78 and the clathrin-mediated endocytosis pathway were silenced by RNAi, and this approach resulted in a 90% reduction of DENV-infected cells⁷⁰. Also, a recent report showed that siRNA toward the TNF- α gene reduced cytokine response in DENV-infected DCs, highlighting the potential of targeted RNAi-based approaches to simultaneously decrease viral replication and the detrimental host immune response⁶⁵.

3.3. Japanese encephalitis virus and Yellow fever virus

Although effective vaccination against JEV and YFV are currently available, these viruses remain a major public health problem that threat hundreds of millions of people living in endemic regions and to people traveling to these regions. The annual estimated incidence of JEV and YFV infections is 50,000 and 200,000 cases with a mortality rate of 25% and 15%, respectively^{4,71}.

JEV is transmitted through a zoonotic cycle between mosquitoes, pigs, and water birds. Humans are only accidentally infected. The primary mosquito vector of JEV is *Culex tritaeniorhynchus*, but species such as *Cx. gelidus*, *Cx. fuscocephala*, and *Cx. annulirostris* are important secondary or regional vectors⁷². For YFV, several species of the *Aedes* and *Haemagogus* mosquitoes are important for transmission. The vertebrate hosts of YFV are monkeys and humans, and the mosquitoes transmit the virus from one host to another⁴. The continuous geographical expansion of

the mosquito vectors of JEV and YFV and the difficulties to implement a worldwide vaccination program highlights the need for a specific antiviral therapy.

The effectiveness of RNAi to inhibit YFV replication was described by Pacca and coworkers⁷³. Vero cells stably transfected with a shRNA targeting the NS1 or the E gene decreased YFV infection in 97% and 68%, respectively. Administration of these shRNAs to mice 12 h prior to YFV challenge increased the survival rate in 40% (siRNA toward NS1) and 20% (siRNA toward E)⁷³.

The effect of RNAi in JEV replication has been examined in vitro and in vivo. JEV replication was attenuated in BHK-21 and HEK-293T cells transfected with a shRNA targeting the NS5 gene 5 h prior to infection^{74,75}. In addition, Kumar and coworkers reported that JEV infection is almost completely abolished in Vero cells and Neuro 2a cells prior transduced with a shRNA directed to the E gene. Importantly, all mice survived JEV infection when treated with shRNA 0.5 or 6 h postchallenge⁷⁶. The use of several siRNAs to target multiple sites along the genome of JEV has also been reported. Wu et al. constructed a single polycistron to simultaneously express nine siRNAs-targeting eight genes of JEV (PrM, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Transfection of BHK-21 cells with this construct inhibited replication of three wild-type JEV strains belonging to two different genotypes⁷⁷. Furthermore, efficient inhibition of infection was seen using recombinant JEV carrying MREs. Yen et al. inserted two copies of the MRE for miR-124 in the 3'UTR of JEV. None of the mice challenged with this virus died from infection, whereas virus challenged with the wild-type strain or with a virus carrying a mutated MRE was lethal for all mice. Interestingly, immunization with the JEV carrying the MRE for miR-124 elicited protective immunity against subsequent lethal challenge with wild-type JEV⁷⁸.

4. RNAi and the mosquito vector

The vast majority of mosquitoes become infected with an arbovirus when they take a blood meal from a viremic vertebrate host. Viral amplification begins with the infection of midgut epithelium cells which is followed by dissemination of the virus to the salivary glands and other tissues. Once the virus is present in saliva, a female mosquito transmits the virus to a new host while taking blood meal⁷⁹. Despite efficient virus replication, minimal pathology is seen in the mosquito vector⁸⁰. This suggests the presence of evolutionary mechanisms that allow virus replication without jeopardizing the host and transmission. Indeed, it has been suggested that RNAi is a key component of the innate immune response of mosquitoes to viral infections⁸¹. In previous sections, we have described that an exogenous trigger of the RNAi pathway in mosquito-cultured cells^{59–62} and *A. aegypti* mosquitoes^{59–62}

can mediate resistance against flaviviruses. In addition, it has been shown that WNV⁸² and DENV infection⁸³ of *Drosophila* cell lines induce functional virus-specific siRNAs that promote a protective RNAi response. Although the production of DENV-specific siRNAs has also been reported in Aag2 cells and orally infected *A. aegypti* mosquitoes, it seems that the virus can somehow circumvent the natural RNAi response, since persistent infection is observed in both cases^{84,85}. Furthermore, impairment of the RNAi pathway was found to increase viral replication^{84,85}. Taken together, these observations suggest that the RNAi response in mosquitoes controls virus replication to such an extent that it prevents pathology in the infected host but is sufficiently high to allow transmission of the virus to a new host.

Furthermore, the exploitation of RNAi to reduce vector competence for Flavivirus infection has been suggested, especially since traditional approaches for vector control have failed⁸⁶. Significant progress has been made in this area with *A. aegypti*, the major vector of DENV. Female mosquitoes genetically manipulated with germ line transgenes to express dsRNA derived from the prM gene of DENV-2 in their midguts have a high level of resistance toward DENV-2 infection and a reduced ability to transmit the virus⁸⁷. The resistant phenotype of the transgenic mosquitoes was maintained for 13 generations; however, from G14 it became weaker and eventually it was lost in G17. The loss of resistance was caused by the inhibition of the transgene expression, but the explanation for this phenomenon remains unclear⁸⁸. As the authors pointed out, considerations in the transgene design –such as the potential risk for the modified mosquitoes and the ability of the transgene to be inherited and expressed– should be taken into account if a strategy of population replacement will be applied in the field.

5. The interplay between arthropod-borne flaviviruses and the endogenous host cell RNAi pathway

So far we have described the antiviral effect of the RNAi mechanism induced by exogenous delivery of siRNA or precursors, and how cellular miRNA can target sequences artificially introduced within the genome of flaviviruses. In recent years, the naturally occurring interactions between viruses and the host-cellular RNAi pathway have also been highlighted. Viral infections induce profound changes in the miRNA expression profile of the host cell. These changes may represent an additional mechanism of the innate immune response and/or are induced by the virus in order to promote reproduction⁸⁹. There are only a few reports available describing how arthropod-borne flaviviruses influence the miRNA expression of their host cells. Skalsky *et al.*⁹⁰, observed downregulation of miR-989 and overexpression of miR-

92 in *Cx. quinquefasciatus* mosquitoes infected with WNV when compared to non-infected mosquitoes. Unfortunately, there is no evidence on the functional role of these miRNAs during WNV infection⁹⁰. It has also been reported that WNV induces upregulation of miRNA Hs_154 in infected neuronal cells and in the central nervous system tissue of infected mice. Hs_154 targets the mRNA of the antiapoptotic proteins, CCCTC-binding factor (CTCF), and EGFR-coexpressed protein (ECOP). The authors hypothesize that the upregulation of Hs_154 is a cellular antiviral response to the infection since downregulation of CTCF and ECOP contributes to cell death⁹¹.

In addition to cellular miRNAs, many virally encoded miRNAs have been identified. Viral miRNAs have been described to regulate both, cellular and viral gene expression⁹². Although initially cytoplasmic RNA viruses such as flaviviruses were not believed to express miRNAs⁹³, Hussain et al. have reported the generation of a mature miRNA derived from WNV in infected Aag2 and C6/36 cells. The discovered miRNA (KUN-miR-1) upregulates the mosquito GATA4 mRNA level and promotes replication of the virus⁹⁴. Furthermore, as a proof of concept it was shown that functional viral miRNAs can be produced if the pre-miRNA sequence is incorporated into the genome of the virus. For example, TBEV was able to express an Epstein–Barr viral miRNA when the precursor was integrated into the 3'UTR of TBEV genome⁹⁵.

6. Conclusions and challenges

Flavivirus infections represent a severe global public health problem with major individual, social, and economic consequences; therefore, preventive and therapeutic strategies are urgently needed. As we reviewed here, RNAi can be used as a prophylactic and therapeutic agent against flavivirus infections and its associated diseases. Furthermore, we highlighted the possibility to use RNAi in vector control and pathogen transmission. However, many hurdles must be overcome in order to translate the positive in vitro and in vivo data to the clinic and into the fields.

RNAi is based on sequence homology and therefore virtually any sequence can be targeted. Indeed, this review described that many flavivirus genes can be successfully targeted. In addition, mRNAs encoding cellular cofactors for viral replication can be targeted to suppress viral replication. However, careful design of the small RNA sequence must be done since partial homology between small RNAs and unintended mRNA transcripts might result in no-desirable gene silencing⁹⁶. In addition, if the activation of the innate immune response is not desirable, it is critical to avoid sequences that can be recognized by Toll-like receptors⁹⁷. Moreover, during RNAi silencing of viral replication, escape mutants often arise and therefore targeting of conserved regions is preferable as well as the use of multiple RNA molecules

targeting distinct regions^{77,98,99}. Bioinformatic approaches followed up with experimental validation should be applied to determine optimal siRNA sequences that are complementary to the target mRNA, induce minimal immune response, and avoid the appearance of escape mutants. In the case of flaviviruses, highly conserved sequences within the C, NS5 genes and within the 3'UTR might represent excellent targets for RNAi therapies. Furthermore, future research should continue to focus on the complex interplay of arthropod-borne flaviviruses and the RNAi pathway in different host cells to search for novel targets for RNAi-based intervention.

Perhaps, the biggest challenge in the development of successful siRNA-based drugs lies within the design of a safe and effective delivery system targeting biological relevant cell types. This is a complex task with multiple demands, including slow excretion, high stability in blood serum, limited nonspecific accumulation in tissues, efficient cellular uptake, and intracellular release. The most commonly applied delivery systems to date are lipid-based carriers, antibodies, peptides, and nanoparticles conjugates¹⁰⁰. Recently, a clinical trial with patients having solid cancers showed inhibition of gene expression using siRNA-targeted nanoparticles that were administered systemically¹⁰¹. This technology was also found effective in a cell culture model of HCV infection¹⁰². Alternatively, as was mentioned above, Subramanya and coworkers success-fully linked an siRNA molecule to a peptide able to bind specifically to human MDDC, one of the main targets of DENV⁶⁵. Future research is required to further characterize the potential of these and other delivery systems to combat flavivirus infections.

In addition, we must keep in mind that for the elimination of flavivirus infections, we most likely need an integrated approach that includes vaccination, enhanced mosquito control, and improved clinical management.

Acknowledgments

This work was supported by Colciencias–Colombia, grant 1115-519-28777 and Convocatoria nacional 528 para estudios de doctorados en Colombia año 2011, by Jan Kornelis de Cock Foundation (February 2012–July 2014), and by the Dutch Organization for Scientific research (NWO-VIDI, Earth and Life Sciences).

References

- Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Lippincott Williams & Wilkins, editor. *Fields in Virology*. 5th ed. 2007. p. 115–1252.
- Gould EA, Solomon T. Pathogenic flaviviruses. *Lancet*. 2008 Feb 9;371(9611):500–9.
- World Health Organization. WHO. Dengue and severe dengue - Fact sheet N°117 [Internet]. World Health Organization; 2012. Available from: <http://www.who.int/mediacentre/factsheets/fs117/en/>
- World Health Organization. Japanese encephalitis. Fact sheet N°386 [Internet]. 2012. Available from: <http://www.who.int/mediacentre/factsheets/fs386/en/>
- World Health Organization. West Nile virus. Fact sheet N°354 [Internet]. 2012. Available from: <http://www.who.int/mediacentre/factsheets/fs354/en/>
- World Health Organization. Yellow fever. Fact sheet N°100 [Internet]. 2012. Available from: <http://www.who.int/mediacentre/factsheets/fs100/en/>
- Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? *Curr Opin Immunol*. 2009;21(3):308–13.
- Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. *Clin Infect Dis*. 2010 Apr 15;50(8):1155–64.
- Heinz FX, Holzmann H, Essl A, Kundl M. Field effectiveness of vaccination against tick-borne encephalitis. *Vaccine*. 2007;25(43):7559–67.
- Sidahmed AME, Wilkie B. Endogenous Antiviral Mechanisms of RNA Interference: A Comparative Biology Perspective. *Methods Mol Biol*. 2010;623:3–19.
- Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. *Cell*. 2009 Feb 20;136(4):642–55.
- Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. *Nat Rev Mol Cell Biol*. 2009 Feb;10(2):126–39.
- SHI Y, YANG DH, XIONG J, JIA J, HUANG B, JIN YX. Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs. *Cell Res*. 2005;15(3):193–200.
- Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, et al. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. *Immunity*. 2007 Jul;27(1):123–34.
- Ahluwalia JK, Khan SZ, Soni K, Rawat P, Gupta A, Hariharan M, et al. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. *Retrovirology*. 2008 Jan;5:117.
- Song L, Liu H, Gao S, Jiang W, Huang W. Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. *J Virol*. 2010 Sep;84(17):8849–60.
- Pfeffer S, Baumert TF. Impact of microRNAs for pathogenesis and treatment of hepatitis C virus infection. *Gastroenterol Clin Biol*. 2010;34:431–5.
- Lee Y, Kim M, Han J, Yeom K-H, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. *Embo J*. 2004;23(20):4051–60.
- Landthaler M, Yalcin A, Tuschl T. The Human DiGeorge Syndrome Critical Region Gene 8 and Its D. melanogaster Homolog Are Required for miRNA Biogenesis. *Curr Biol*. 2004;14(0):2162–7.
- Lee Y, Jeon K, Lee J-T, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. *EMBO J*. 2002 Sep 2;21(17):4663–70.
- Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. *Science*. 2004 Jan 2;303(5654):95–8.
- Bernstein E, Caudy a a, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature*. 2001 Jan 18;409(6818):363–6.
- Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009 Jan 23;136(2):215–33.
- Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet*. 2008 Feb;9(2):102–14.
- Amarzguioi M, Rossi JJ, Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. *FEBS Lett*. 2005;579(26):5974–81.
- Hammond SM, Caudy a a, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. *Nat Rev Genet*. 2001 Feb;2(2):110–9.
- Elbashir SM, Harborth J, Lendeckel W, Yalcin a, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*. 2001 May 24;411(6836):494–8.
- Dykxhoorn DM, Novina CD, Sharp P a. Killing the messenger: short RNAs that silence

- gene expression. *Nat Rev Mol Cell Biol.* 2003 Jun;4(6):457–67.
29. Segers GC, Zhang X, Deng F, Sun Q, Nuss DL. Evidence that RNA silencing functions as an antiviral defense mechanism in fungi. *Proc Natl Acad Sci.* 2007;104(31):12902–6.
 30. Voinnet O. RNA silencing as a plant immune system against viruses. *Trends Genet.* 2001;17(8):449–59.
 31. Wilkins C, Dishongh R, Moore SC, Whitt MA, Chow M, Machaca K. RNA interference is an antiviral defence mechanism in *Caenorhabditis elegans*. *Nature.* 2005;436(7053):1044–7.
 32. Parameswaran P, Sklan E, Wilkins C, Burgon T, Samuel M a, Lu R, et al. Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. *PLoS Pathog.* 2010 Feb;6(2):e1000764.
 33. Yeung ML, Bennasser Y, Watashi K, Le SY, Houzet L, Jeang KT. Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: Evidence for the processing of a viral-cellular double-stranded RNA hybrid. *Nucleic Acids Res.* 2009;37(19):6575–86.
 34. Haasnoot J, Berkhout B. RNAi and cellular miRNAs in infections by mammalian viruses. In: Rij RP, editor. *Antiviral RNAi: Concepts, Methods, and Applications, Methods in Molecular Biology.* Totowa, NJ: Humana Press; 2011. (Methods in Molecular Biology; vol. 721).
 35. Lecellier C, Dunoyer P, Arar K, Lehmann-che J, Eyquem S, Voinnet O. A Cellular MicroRNA Mediates Antiviral Defense in Human Cells. *Science* (80-). 2005;308:557.
 36. Lindenbach BD, Rice CM. *Flaviviridae: The viruses and their replication.* In: Knipe D., Howley PM, editors. *Fields virology.* 5th ed. Philadelphia: Lippincott-Raven Publishers; 2007. p. 1101–52.
 37. Markoff L. 5'- and 3'-noncoding regions in flavivirus RNA. *Adv Virus Res.* 2003;59:177–228.
 38. Stiasny K, Fritz R, Pangerl K, Heinz FX. Molecular mechanisms of flavivirus membrane fusion. *Amino Acids.* 2011 Nov;41(5):1159–63.
 39. Smit JM, Moesker B, Rodenhuis-Zybert I, Wilschut J. Flavivirus cell entry and membrane fusion. *Viruses.* 2011 Feb;3(2):160–71.
 40. Urcuqui-inchima S, Patin C, Di FJ. Recent developments in understanding dengue virus replication. *Adv Virus Res.* 2010;77(10).
 41. Mackenzie JM, Jones MK, Westaway EG. Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. *J Virol.* 1999;73(11):9555–67.
 42. Villordo SM, Gamarnik A V. Genome cyclization as strategy for flavivirus RNA replication. *Virus Res.* 2009 Feb;139(2):230–9.
 43. Davidson AD. Chapter 2 New Insights into Flavivirus Nonstructural Protein 5. 1st ed. Vol. 74, *Advances in Virus Research.* Elsevier Inc.; 2009. 41–101 p.
 44. Maeda A, Maeda J, Takagi H, Kurane I. Detection of small RNAs containing the 5'- and the 3'-end sequences of viral genome during West Nile virus replication. *Virology.* 2008 Feb 5;371(1):130–8.
 45. Ivanyi-Nagy R, Darlix J-L. Intrinsic disorder in the core proteins of flaviviruses. *Protein Pept Lett.* 2010;17(8):1019–25.
 46. Perera R, Kuhn RJ. Structural proteomics of dengue virus. *Curr Opin Microbiol.* 2008;11(4):369–77.
 47. Fernandez-Garcia M-D, Mazzon M, Jacobs M, Amara A. Pathogenesis of flavivirus infections: using and abusing the host cell. *Cell Host Microbe.* 2009 Apr 23;5(4):318–28.
 48. Ulbert S. West Nile virus: the complex biology of an emerging pathogen. *Intervirology.* 2011 Jan;54(4):171–84.
 49. McCown M, Diamond MS, Pekosz A. The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. *Virology.* 2003 Sep;313(2):514–24.
 50. Ong SP, Choo BGH, Chu JH, Ng ML. Expression of vector-based small interfering RNA against West Nile virus effectively inhibits virus replication. *Antiviral Res.* 2006 Dec;72(3):216–23.
 51. Bai F, Wang T, Pal U, Bao F, Gould LH, Fikrig E. Use of RNA interference to prevent lethal murine west nile virus infection. *J Infect Dis.* 2005 Apr 1;191(7):1148–54.
 52. Yang Y, Wu C, Wu J, Nerurkar VR, Lu Y. Inhibition of West Nile Virus Replication by Retrovirus-Delivered Samll Interfering RNA in Human Neuroblastoma Cells. *J Med Virol.* 2008;80(5):930–6.
 53. Anthony KG, Bai F, Krishnan MN, Fikrig E, Koski R a. Effective siRNA targeting of the 3' untranslated region of the West Nile virus genome. *Antiviral Res.* 2009 Jun;82(3):166–8.
 54. Geiss BJ, Pierson TC, Diamond MS. Actively replicating West Nile virus is resistant to

- cytoplasmic delivery of siRNA. *Virology*. 2005 Jan;2:53.
55. Takigawa Y, Nagano-Fujii M, Deng L, Hidajat R, Tanaka M, Mizuta H, et al. Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. *Microbiol Immunol*. 2004;48(8):591–8.
 56. Ye C, Abraham S, Wu H, Shankar P, Manjunath N. Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. *PLoS One*. 2011 Jan;6(3):e17889.
 57. Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. *Clin Vaccine Immunol*. 2010 Dec;17(12):1829–35.
 58. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. *Curr Opin Infect Dis*. 2006 Oct;19(5):429–36.
 59. Adelman ZN, Blair CD, Carlson JO, Beaty BJ, Olson KE. Sindbis virus-induced silencing of dengue viruses in mosquitoes. *Insect Mol Biol*. 2001 Jun;10(3):265–73.
 60. Adelman ZN, Sanchez-vargas I, Travanty EA, Carlson JO, Beaty BJ, Blair CD, et al. RNA Silencing of Dengue Virus Type 2 Replication in Transformed C6 / 36 Mosquito Cells Transcribing an Inverted-Repeat RNA Derived from the Virus Genome. 2002;76(24):12925–33.
 61. Gaines PJ, Olson KE, Higgs S, Powers a M, Beaty BJ, Blair CD. Pathogen-derived resistance to dengue type 2 virus in mosquito cells by expression of the premembrane coding region of the viral genome. *J Virol*. 1996;70(4):2132–7.
 62. Olson KE, Adelman ZN, Travanty E a, Sanchez-Vargas I, Beaty BJ, Blair CD. Developing arbovirus resistance in mosquitoes. *Insect Biochem Mol Biol*. 2002 Oct;32(10):1333–43.
 63. Wu X, Hong H, Yue J, Wu Y, Li X, Jiang L, et al. Inhibitory effect of small interfering RNA on dengue virus replication in mosquito cells. *Virology*. 2010 Jan;7(1):270.
 64. Zhang W, Singam R, Hellermann G, Kong X, Juan HS, Lockey RF, et al. Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. *Genet Vaccines Ther*. 2004 Aug 9;2(1):8.
 65. Subramanya S, Kim S-S, Abraham S, Yao J, Kumar M, Kumar P, et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. *J Virol*. 2010 Mar;84(5):2490–501.
 66. Stein D a, Perry ST, Buck MD, Oehmen CS, Fischer M a, Poore E, et al. Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. *J Virol*. 2011 Oct;85(19):10154–66.
 67. Heiss BL, Maximova O a, Thach DC, Speicher JM, Pletnev AG. MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype. *J Virol*. 2012 May;86(10):5647–59.
 68. Lee T-C, Lin Y-L, Liao J-T, Su C-M, Lin C-C, Lin W-P, et al. Utilizing liver-specific microRNA-122 to modulate replication of dengue virus replicon. *Biochem Biophys Res Commun*. 2010 Jun 4;396(3):596–601.
 69. Padwad YS, Mishra KP, Jain M, Chanda S, Karan D, Ganju L. RNA interference mediated silencing of Hsp60 gene in human monocytic myeloma cell line U937 revealed decreased dengue virus multiplication. *Immunobiology*. 2009;214(6):422–9.
 70. Alhoot MA, Wang SM, Sekaran SD. RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells. *PLoS One*. 2012 Jan;7(3):e34060.
 71. Misra UK, Kalita J. Overview: Japanese encephalitis. *Prog Neurobiol*. 2010 Jun;91(2):108–20.
 72. van den Hurk AF, Ritchie S a, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. *Annu Rev Entomol*. 2009 Jan;54:17–35.
 73. Pacca CC, Severino A a, Mondini A, Rahal P, D'avila SGP, Cordeiro JA, et al. RNA interference inhibits yellow fever virus replication in vitro and in vivo. *Virus Genes*. 2009 Apr;38(2):224–31.
 74. Liu X, Cao S, Zhou R, Xu G, Xiao S, Yang Y, et al. Inhibition of Japanese encephalitis virus NS1 protein expression in cell by small interfering RNAs. *Virus Genes*. 2006 Aug;33(1):69–75.
 75. Qi W-B, Hua R-H, Yan L-P, Tong G-Z, Zhang G-H, Ren T, et al. Effective inhibition of Japanese encephalitis virus replication by small interfering RNAs targeting the NS5 gene. *Virus Res*. 2008 Mar;132(1–2):145–51.
 76. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. *PLoS Med*. 2006 Apr;3(4):e96.
 77. Wu Z, Xue Y, Wang B, Du J, Jin Q. Broad-spectrum antiviral activity of RNA

- interference against four genotypes of Japanese encephalitis virus based on single microRNA polycistrons. *PLoS One*. 2011 Jan;6(10):e26304.
78. Yen LC, Lin YL, Sung HH, Liao JT, Tsao CH, Su CM, et al. Neurovirulent flavivirus can be attenuated in mice by incorporation of neuron-specific microRNA recognition elements into viral genome. *Vaccine*. 2013;31(49):5915–22.
 79. Kuno G, Chang GJ. Biological Transmission of Arboviruses: Reexamination of and New Insights into Components, Mechanisms, and Unique Traits as Well as Their Evolutionary Trends. 2005;18(4):608–37.
 80. Lambrechts L, Scott TW. Mode of transmission and the evolution of arbovirus virulence in mosquito vectors. *Proc Biol Sci*. 2009 Apr 7;276(1660):1369–78.
 81. Blair CD. Mosquito RNAi is the major innate immune pathway controlling arbovirus infection and transmission. *Futur Microbiol*. 2011;6(3):265–77.
 82. Chotkowski HL, Ciota AT, Jia Y, Puig-Basagoiti F, Kramer LD, Shi PY, et al. West Nile virus infection of *Drosophila melanogaster* induces a protective RNAi response. *Virology*. 2008;377(1):197–206.
 83. Mukherjee S, Hanley K a. RNA interference modulates replication of dengue virus in *Drosophila melanogaster* cells. *BMC Microbiol*. 2010 Jan;10(Figure 1):127.
 84. Brackney DE, Scott JC, Sagawa F, Woodward JE, Miller N a, Schilkey FD, et al. C6/36 *Aedes albopictus* cells have a dysfunctional antiviral RNA interference response. *PLoS Negl Trop Dis*. 2010 Jan;4(10):e856.
 85. Sánchez-Vargas I, Scott JC, Poole-Smith BK, Franz AWE, Barbosa-Solomieu V, Wilusz J, et al. Dengue virus type 2 infections of *Aedes aegypti* are modulated by the mosquito's RNA interference pathway. *PLoS Pathog*. 2009 Feb;5(2):e1000299.
 86. Beaty BJ. Control of arbovirus diseases: is the vector the weak link? *Arch Virol Suppl*. 2005;(19):73–88.
 87. Franz AWE, Sanchez-Vargas I, Adelman ZN, Blair CD, Beaty BJ, James A a, et al. Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified *Aedes aegypti*. *Proc Natl Acad Sci U S A*. 2006 Mar 14;103(11):4198–203.
 88. Franz a WE, Sanchez-Vargas I, Piper J, Smith MR, Khoo CCH, James a a, et al. Stability and loss of a virus resistance phenotype over time in transgenic mosquitoes harbouring an antiviral effector gene. *Insect Mol Biol*. 2009 Oct;18(5):661–72.
 89. Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. *Annu Rev Microbiol*. 2010 Jan;64:123–41.
 90. Skalsky RL, Vanlandingham DL, Scholle F, Higgs S, Cullen BR. Identification of microRNAs expressed in two mosquito vectors, *Aedes albopictus* and *Culex quinquefasciatus*. *BMC Genomics*. 2010 Jan;11:119.
 91. Smith JL, Grey FE, Uhrlaub JL, Nikolich-zugich J, Hirsch AJ. Induction of the Cellular MicroRNA, Hs _ 154, by West Nile Virus Contributes to Virus-Mediated Apoptosis through Repression of Antiapoptotic Factors. 2012;5278–87.
 92. Grundhoff A, Sullivan CS. Virus-encoded microRNAs. *Virology*. 2011 Mar 15;411(2):325–43.
 93. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer F a, et al. Identification of microRNAs of the herpesvirus family. *Nat Methods*. 2005;2(4):269–76.
 94. Hussain M, Torres S, Schnettler E, Funk A, Grundhoff A, Pijlman GP, et al. West Nile virus encodes a microRNA-like small RNA in the 3' untranslated region which up-regulates GATA4 mRNA and facilitates virus replication in mosquito cells. *Nucleic Acids Res*. 2012 Mar;40(5):2210–23.
 95. Rouha H, Thurner C, Mandl CW. Functional microRNA generated from a cytoplasmic RNA virus. *Nucleic Acids Res*. 2010 Dec;38(22):8328–37.
 96. Jackson AL. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. *RNA*. 2006;12(7):1179–87.
 97. Robbins M, Judge A, MacLachlan I. siRNA and Innate Immunity. *Oligonucleotides*. 2009;19(2):89–102.
 98. Sugiyama R, Habu Y, Ohnari A, Miyano-Kurosaki N, Takaku H. RNA interference targeted to the conserved dimerization initiation site (DIS) of HIV-1 restricts virus escape mutation. *J Biochem*. 2009;146(4):481–9.
 99. Zhang T, Cheng T, Wei L, Cai Y, Yeo A, Han J, et al. Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. *Virol J*. 2012;9(1):118.
 100. Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. *FEBS J*. 2010 Dec;277(23):4814–27.

101. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi C a, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. *Nature*. 2010 Apr 15;464(7291):1067–70.
102. Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, Ooms T, et al. Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes. *Mol Ther*. 2012;20(9):1724–36.

